| name | genryzon-red-flag-monitoring |
| description | Red-flag safety scan for a child on Genryzon (somatrogon, weekly long-acting growth hormone) — recognise and act on the treatment-emergent adverse events that require holding, investigating, or stopping the drug. Covers benign intracranial hypertension, slipped capital femoral epiphysis, pancreatitis, injection-site myositis (m-cresol), scoliosis progression, second neoplasm surveillance in cancer survivors, hyperglycaemia unmasking, and adrenal insufficiency unmasking. Use when a clinician asks what side effects to watch for on Genryzon, red flags on weekly GH, headache in a child on somatrogon, limp in a child on GH, abdominal pain on Genryzon, or is following up a paediatric GHD patient on somatrogon. Grounded in the Pfizer India Product Monograph (Genryzon LPD, 2022 — PfLEET 2022-0081166). |
Genryzon Red-Flag Monitoring
Safety net for a child already on somatrogon. Walk this scan at every follow-up visit and any time the family reports a new symptom.
Step 1 — Symptom-triggered scan at every visit
Ask the family (and the child directly if age-appropriate) about each of the following since the last visit. Any positive → move to the matching Step 2 workup.
| Symptom | Suspect |
|---|
| Persistent headache; vision changes; nausea/vomiting; papilloedema | Benign intracranial hypertension |
| New limp; hip pain; knee pain (referred from hip) | Slipped capital femoral epiphysis (SCFE) |
| Severe or persistent abdominal pain | Pancreatitis |
| Localised injection-site myalgia; disproportionate pain at injection sites | Myositis (m-cresol excipient) |
| Back curvature progression; asymmetry of shoulders/hips; scoliosis on inspection | Scoliosis progression |
| New neurological symptom in a childhood cancer survivor with prior cranial radiation | Second neoplasm (esp. meningioma) |
| Polyuria, polydipsia, weight loss, or rising HbA1c | Somatrogon-induced hyperglycaemia |
| Fatigue, hypotension, weight loss, hypoglycaemia, hyponatraemia | Unmasked central hypoadrenalism |
| Fatigue, cold intolerance, constipation, poor growth despite therapy | Unmasked central hypothyroidism |
| New hypersensitivity: rash, angioedema, wheeze, anaphylaxis | Systemic hypersensitivity |
Step 2 — Specific workup and immediate action per red flag
Benign intracranial hypertension (IH)
Workup:
- Fundoscopy — look for papilloedema
- Neurological exam
- CT/MRI brain to exclude a mass
- If exam consistent with IH → LP for opening pressure (per neurology)
Action:
- Temporarily discontinue somatrogon
- Refer to neurology / neuro-ophthalmology
- Restart cautiously only after resolution, with close monitoring. There is no consensus rule for restart timing; document the joint decision with neurology
Slipped capital femoral epiphysis (SCFE)
Workup:
- Urgent hip / knee X-ray (AP and frog-lateral of both hips)
- Refer to paediatric orthopaedics
Action:
- Non-weight-bearing until orthopaedic review — SCFE can worsen with continued weight-bearing
- Somatrogon can generally be continued once SCFE is managed, but discuss with orthopaedic team
Pancreatitis
Workup:
- Serum lipase and amylase
- Ultrasound / CT abdomen if levels elevated or persistent pain
- Look for other precipitants (gallstones, hypertriglyceridaemia, drugs)
Action:
- Hold somatrogon during acute episode
- Standard pancreatitis management (fluids, pain control, NPO if severe)
- Restart only after full resolution, with careful monitoring
Injection-site myositis (m-cresol)
Workup:
- Clinical assessment — disproportionate pain, tenderness, swelling at injection sites
- CPK if diffuse myalgia
- MRI of affected muscle if severe or persistent
Action:
- Switch to a metacresol-free growth hormone product (m-cresol is the preservative in Genryzon)
- Local supportive care
Scoliosis progression
Workup:
- Adam's forward bend test
- Standing spinal X-ray (Cobb angle)
- Refer to paediatric orthopaedics / spinal team if Cobb ≥20° or rapid progression
Action:
- Somatrogon can generally be continued — GH does not directly cause scoliosis but rapid growth may reveal or worsen it
- Manage the scoliosis per orthopaedic protocol (bracing, surgery as indicated)
Second neoplasm — childhood cancer survivors
Focus on:
- Cranial radiation history → meningioma is the most-reported second tumour on GH
- New neurological symptom, headache, cranial nerve deficit, focal deficit → MRI brain
- Any suspicious skin or somatic lump → biopsy per oncology
Action:
- Loop oncology in early for any concerning symptom
- Adhere to the survivor's baseline surveillance schedule
- If second neoplasm is confirmed → discontinue somatrogon and manage the neoplasm
Somatrogon-induced hyperglycaemia
Workup:
- Fasting plasma glucose + HbA1c
- OGTT if borderline
Action:
- Diabetes at diagnosis → involve paediatric diabetologist; escalate insulin/OAD as needed. Somatrogon can usually continue but with tight glucose monitoring
- Pre-diabetes → lifestyle intensification, monitor more frequently
- Insulin-treated child already → up-titrate insulin doses as needed
Unmasked central hypoadrenalism
Workup:
- Morning cortisol
- ACTH stimulation test / ITT if borderline
Action:
- If adrenal crisis suspected → treat as adrenal crisis first: IV hydrocortisone, IV fluids, glucose. Investigate afterwards
- If confirmed central hypoadrenalism → start (or escalate) hydrocortisone replacement. Continue somatrogon
- If child already on hydrocortisone replacement → dose may need to be increased on GH (GH ↓ cortisone→cortisol conversion)
Unmasked central hypothyroidism
Workup:
- TSH + free T4 (interpret carefully — in central hypothyroidism, TSH may be normal or inappropriately low despite low fT4)
Action:
- Start or up-titrate levothyroxine — untreated hypothyroidism blunts response to GH
- Recheck TFTs 6–8 weeks after any thyroxine change
Systemic hypersensitivity
Action:
- Immediately discontinue Genryzon
- Standard anaphylaxis management (adrenaline IM, airway support, IV fluids, corticosteroids, antihistamines)
- Do not rechallenge — switch to a somatrogon-free growth hormone product after specialist review
Step 3 — Scheduled monitoring at every 6–12 month visit (more often in puberty)
Even without new symptoms, at each planned visit check:
- Auxology: height, weight, height velocity (cm/yr), BMI
- Bone age — annually or as indicated
- Tanner stage
- IGF-1 (day 4 post-dose — see
genryzon-igf1-titration)
- TSH + free T4
- Fasting glucose ± HbA1c
- Fundoscopy if any suspicious symptom
- Spinal inspection for scoliosis
- Pubertal progression and, in girls, review of oral estrogen / OCP use
Guardrails
- Headache in a child on somatrogon is intracranial hypertension until proven otherwise — do not attribute to common causes without a fundoscopy
- Any limp or hip/knee pain in a child on GH warrants a same-week hip X-ray for SCFE — this diagnosis is regularly missed and delayed diagnosis worsens the outcome
- Injection-site myalgia is not "normal soreness" — it can be m-cresol myositis and mandates a switch of GH product
- Childhood cancer survivors on GH need active surveillance for second neoplasm — a neurological complaint is never "just growing pains" in this group
- Adrenal crisis can present as vague fatigue and abdominal pain — a low threshold for morning cortisol / stress-dose steroids in any child on GH who becomes unwell
- Never dismiss papilloedema on baseline fundus and continue GH — that's a signal that pre-existing IH was missed and now the drug will worsen it
- Somatrogon does not need to be permanently stopped for most of these events — most can be resumed after the underlying issue is addressed, except confirmed second neoplasm and severe hypersensitivity, which are absolute stops
Related MD2SKILL skills
genryzon-prescribing-guide — starting dose, injection technique, monitoring cadencegenryzon-igf1-titration — how to interpret and act on IGF-1 SDSgenryzon-pretreatment-screening — baseline work-up before first dosegenryzon-drug-interactions — glucocorticoid, insulin, thyroxine, oral estrogen adjustmentsgenryzon-treatment-discontinuation — when to stop growth hormone entirely
Source
Pfizer Products India Pvt. Ltd. GENRYZON® (Somatrogon) Solution for Injection in Pre-filled Pen — Prescribing Information (India). LPD version 2022-0081166 (PfLEET 2022-0081166). Section 4.4 "Special Warnings and Precautions for Use" and Section 4.8 "Undesirable Effects".
